(Q28303675)

7

object named as

Kayla F Laserson

0 references

author name string

Vaira Leimane

1

0 references

Vija Riekstina

2

0 references

Timothy H Holtz

3

0 references

Evija Zarovska

4

0 references

Vija Skripconoka

5

0 references

Kayla F Laserson

7

0 references

Charles D Wells

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

8

0 references

language of work or name

English

0 references

publication date

January 2005

1 reference

0 references

365

0 references

issue

9456

0 references

page(s)

318-26

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Increasing transparency in partnerships for health--introducing the Green Light Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Treatment of multidrug-resistant tuberculosis in Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Treatment of multidrug-resistant tuberculosis in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

The treatment of multidrug-resistant tuberculosis in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021

Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917786-1

7 January 2021